A distinct epigenetic signature at targets of a leukemia protein

BackgroundHuman myelogenous leukemia characterized by either the non random t(8; 21)(q22; q22) or t(16; 21)(q24; q22) chromosome translocations differ for both their biological and clinical features. Some of these features could be consequent to differential epigenetic transcriptional deregulation at AML1 targets imposed by AML1-MTG8 and AML1-MTG16, the fusion proteins deriving from the two translocations. Preliminary findings showing that these fusion proteins lead to transcriptional downregulation of AML1 targets, marked by repressive chromatin changes, would support this hypothesis. Here we show that combining conventional global gene expression arrays with the power of bioinformatic genomic survey of AML1-consensus sequences is an effective strategy to identify AML1 targets whose transcription is epigenetically downregulated by the leukemia-associated AML1-MTG16 protein.ResultsWe interrogated mouse gene expression microarrays with probes generated either from 32D cells infected with a retroviral vector carrying AML1-MTG16 and unable of granulocyte differentiation and proliferation in response to the granulocyte colony stimulating factor (G-CSF), or from 32D cells infected with the cognate empty vector. From the analysis of differential gene expression alone (using as criteria a p value < 0.01 and an absolute fold change > 3), we were unable to conclude which of the 37 genes downregulated by AML1-MTG16 were, or not, direct AML1 targets. However, when we applied a bioinformatic approach to search for AML1-consensus sequences in the 10 Kb around the gene transcription start sites, we closed on 17 potential direct AML1 targets. By focusing on the most significantly downregulated genes, we found that both the AML1-consensus and the transcription start site chromatin regions were significantly marked by aberrant repressive histone tail changes. Further, the promoter of one of these genes, containing a CpG island, was aberrantly methylated.ConclusionThis study shows that a leukemia-associated fusion protein can impose a distinct epigenetic repressive signature at specific sites in the genome. These findings strengthen the conclusion that leukemia-specific oncoproteins can induce non-random epigenetic changes.

[1]  Daiya Takai,et al.  The CpG Island Searcher: A new WWW resource , 2003, Silico Biol..

[2]  T. Iwakuma,et al.  Organization and expression of the mouse gene for DNA repair methyltransferase. , 1996, DNA and cell biology.

[3]  M. Lübbert,et al.  Upstream and downstream targets of RUNX proteins , 2003, Journal of cellular biochemistry.

[4]  J. Herman,et al.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  Charles Elkan,et al.  Fitting a Mixture Model By Expectation Maximization To Discover Motifs In Biopolymer , 1994, ISMB.

[6]  T. Evans.  Regulation of hematopoiesis by retinoid signaling. , 2005, Experimental hematology.

[7]  John M. Maris,et al.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia , 1999, Nature Genetics.

[8]  T. Nagase,et al.  The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family. , 1998, Blood.

[9]  J. Herman,et al.  Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer , 2004, Oncogene.

[10]  Z. Dauter,et al.  The tetramer structure of the Nervy homology two domain, NHR2, is critical for AML1/ETO's activity. , 2006, Cancer cell.

[11]  A. Hoogeveen,et al.  The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16; 21)-positive myeloid malignancies , 2002, Oncogene.

[12]  J. Kinet,et al.  The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. , 1999 .

[13]  François Fuks,et al.  DNA methylation and histone modifications: teaming up to silence genes. , 2005, Current opinion in genetics & development.

[14]  S. Gerson.  MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.

[15]  M. Ohki,et al.  Interaction and functional cooperation of the leukemia‐associated factors AML1 and p300 in myeloid cell differentiation , 1998, The EMBO journal.

[16]  Michael C. Ostrowski,et al.  TFEC is a macrophage-restricted member of the microphthalmia-TFE subfamily of basic helix-loop-helix leucine zipper transcription factors. , 1999, Journal of immunology.

[17]  Yoshiaki Ito,et al.  Block of granulocytic differentiation of 32Dcl3 cells by AML1/ETO(MTG8) but not by highly expressed Bcl-2 , 1999, Oncogene.

[18]  P. Boccuni,et al.  Transcription factor fusions in acute leukemia: variations on a theme , 2002, Oncogene.

[19]  C. Peterson,et al.  Histones and histone modifications , 2004, Current Biology.

[20]  T. Kouzarides.  Histone methylation in transcriptional control. , 2002, Current opinion in genetics & development.

[21]  H. Drabkin,et al.  Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. , 1992, Blood.

[22]  J. Downing,et al.  Identification of AML-1 and the (8;21) translocation protein (AML-1/ETO) as sequence-specific DNA-binding proteins: the runt homology domain is required for DNA binding and protein-protein interactions , 1993, Molecular and cellular biology.

[23]  S. Pozzi,et al.  A repressive epigenetic domino effect confers susceptibility to breast epithelial cell transformation: implications for predicting breast cancer risk. , 2006, Cancer research.

[24]  S. Nakamura,et al.  Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF. , 2000, Blood.

[25]  J. Altin,et al.  The role of CD45 and CD45‐associated molecules in T cell activation , 1997, Immunology and cell biology.

[26]  S. Minucci,et al.  Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. , 2000, Molecular cell.

[27]  H. Shimada,et al.  Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis , 2002, Leukemia.

[28]  M. Ohki,et al.  t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AML1. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[29]  The Partner Gene of AML1 in t(16;21) Myeloid Malignancies Is a Novel Member of the MTG8(ETO) Family , 1998 .

[30]  P. Watkins,et al.  Transcriptionally active chimeric gene derived from the fusion of the AML1 gene and a novel gene on chromosome 8 in t(8;21) leukemic cells. , 1992, Cancer genetics and cytogenetics.

[31]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[32]  S. Hiebert,et al.  Role of co-repressors in transcriptional repression mediated by the t(8;21), t(16;21), t(12;21), and inv(16) fusion proteins , 2001, Current opinion in hematology.

[33]  I. Touw,et al.  Myeloid maturation block by AML1-MTG16 is associated with Csf1r epigenetic downregulation , 2005, Oncogene.

[34]  T. Kouzarides,et al.  DNA methyltransferases get connected to chromatin. , 2002, Trends in genetics : TIG.

[35]  Hamish S Scott,et al.  AML1 Interconnected Pathways of Leukemogenesis , 2003, Cancer investigation.

[36]  O. Heidenreich,et al.  siRNA-mediated AML1/MTG8 depletion affects differentiation and proliferation-associated gene expression in t(8;21)-positive cell lines and primary AML blasts , 2006, Oncogene.

[37]  S. Minucci,et al.  Methyltransferase Recruitment and DNA Hypermethylation of Target Promoters by an Oncogenic Transcription Factor , 2002, Science.

[38]  J. Herman,et al.  Clinical implications of aberrant DNA methylation patterns in acute myelogenous leukemia , 2005, Annals of Hematology.

[39]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[40]  A. Rosmarin,et al.  Transcriptional regulation in myelopoiesis: Hematopoietic fate choice, myeloid differentiation, and leukemogenesis. , 2005, Experimental hematology.

[41]  Natalia Meani,et al.  Acute myeloid leukemia fusion proteins deregulate genes involved in stem cell maintenance and DNA repair. , 2003, The Journal of clinical investigation.

[42]  B. Hug,et al.  Oligomerization of ETO Is Obligatory for Corepressor Interaction , 2001, Molecular and Cellular Biology.

[43]  S. Berger,et al.  Histone modifications in transcriptional regulation. , 2002, Current opinion in genetics & development.

[44]  T. Yamagata,et al.  Runx1/AML1 in Normal and Abnormal Hematopoiesis , 2005, International journal of hematology.

[45]  Y. Ito,et al.  Negative regulation of granulocytic differentiation in the myeloid precursor cell line 32Dcl3 by ear-2, a mammalian homolog of Drosophila seven-up, and a chimeric leukemogenic gene, AML1/ETO. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Hoogeveen,et al.  The MTG proteins: chromatin repression players with a passion for networking. , 2004, Genomics.

[47]  S. Pozzi,et al.  RAR-mediated epigenetic control of the cytochrome P450 Cyp26a1 in embryocarcinoma cells , 2006, Oncogene.

[48]  D. Hume,et al.  Transcription Factor Tfec Contributes to the IL-4-Inducible Expression of a Small Group of Genes in Mouse Macrophages Including the Granulocyte Colony-Stimulating Factor Receptor1 , 2005, The Journal of Immunology.